| abstract |
The present invention relates to a composition containing Melastoma sanguineum extracts or fractions thereof as active ingredients for preventing or treating diabetic complications. More particularly, Melastoma sanguineum extracts, or ethyl acetate fractions and n-butanol fractions which are systematic fractions thereof, inhibit the formation of advanced glycation end-products as well as the activity of aldose reductases, which may serve as an index of the onset of diabetic complications. The Melastoma sanguineum extracts or ethyl acetate fractions and n-butanol fractions have the effects of potently inhibiting vasodilatation caused by hyperglycemia in zebrafish, which are vertebrates, and inhibiting diabetic complications when administered to animal models for diabetic disease. Therefore, the Melastoma sanguineum extracts or ethyl acetate fractions and n-butanol fractions, which are systematic fractions thereof, according to the present invention may be used as active ingredients for a pharmaceutical composition for preventing and treating diabetic complications. |